Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Colin D. Weekes

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-6287-4334; OpenAlex author ID A5026482426. Sources: ClinicalTrials.gov.

Their work

Papers
48 (first author 3, last author 4)
Trials
2 (principal investigator on 2)
Grants
0
Labs led
1
Collaborators
300
Papers, trials and grants by year

2011: 2 papers · 2012: 2 papers · 2013: none · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 2 papers · 2020: 6 papers · 2021: 7 papers · 2022: 5 papers, 2 trials · 2023: 3 papers · 2024: 5 papers · 2025: 2 papers · 2026: 7 papers

Papers 48

  1. Neoadjuvant Chemotherapy With or Without Radiotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2026.3716↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. Disparities in the diagnosis and management of exocrine pancreatic insufficiency in resectable vs metastatic pancreatic cancer. Co-author DOI 10.1093/oncolo/oyag084↗
  4. Feasibility and acceptability of an electronic decision aid for genetic testing in ovarian and pancreatic cancer patients. Co-author DOI 10.1093/rescon/vmag026↗
  5. Actual Five-year Survival After Neoadjuvant Therapy and Resection for Localized Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000007214↗
  6. Therapeutic Targeting of Epithelial-Mesenchymal Cellular Plasticity in Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-25-2052↗
  7. Immune and stromal features of durable complete response to radiation and dual immune checkpoint blockade in pancreatic cancer Co-author DOI 10.64898/2026.08.06.26359422↗
  8. Perioperative therapy for resectable and borderline resectable pancreatic adenocarcinoma: an Academic Gastrointestinal Cancer Consortium Study. Last author DOI 10.1093/oncolo/oyaf271↗
  9. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  10. The Sequencing Conundrum in Localized Pancreatic Adenocarcinoma-Progress or Passive Acceptance? First author DOI 10.1001/jamaoncol.2024.0870↗
  11. Small steps can lead to substantial breakthroughs: moving the therapeutic needle forward in pancreatic cancer. First author DOI 10.1016/s1470-2045(24)00290-0↗
  12. Feasibility, Safety, and Efficacy of Aggressive Multimodal Management of Elderly Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000006131↗
  13. Establishing a Role for Local Therapy in Oligometastatic Pancreatic Cancer. First author DOI 10.1200/jco-24-01264↗
  14. Collagen type I PET/MRI enables evaluation of treatment response in pancreatic cancer in pre-clinical and first-in-human translational studies. Co-author DOI 10.7150/thno.100116↗
  15. Portal Vein or Superior Mesenteric Vein Thrombosis with Dose-Escalated Radiation for Borderline or Locally Advanced Pancreatic Cancer. Co-author DOI 10.1007/s11605-023-05796-5↗
  16. Phase Ib and Expansion Study of Gemcitabine, Nab-Paclitaxel, and Ficlatuzumab in Patients With Metastatic Pancreatic Cancer. Co-author DOI 10.1093/oncolo/oyad002↗
  17. Tolerability, Attrition Rates, and Survival Outcomes of Neoadjuvant FOLFIRINOX for Nonmetastatic Pancreatic Adenocarcinoma: Intent-to-Treat Analysis. Co-author DOI 10.1097/xcs.0000000000000499↗
  18. Single-nucleus and spatial transcriptome profiling of pancreatic cancer identifies multicellular dynamics associated with neoadjuvant treatment. Co-author DOI 10.1038/s41588-022-01134-8↗
  19. A Combination of Biochemical and Pathological Parameters Improves Prediction of Postresection Survival After Preoperative Chemotherapy in Pancreatic Cancer: Th… Co-author DOI 10.1097/sla.0000000000004143↗
  20. Prospective Phase II Trials Validate the Effect of Neoadjuvant Chemotherapy on Pattern of Recurrence in Pancreatic Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000004585↗
  21. A randomized, phase II trial of oral azacitidine (CC-486) in patients with resected pancreatic adenocarcinoma at high risk for recurrence. Co-author DOI 10.1186/s13148-022-01367-8↗
  22. Supportive Oncology Care at Home Intervention for Patients With Pancreatic Cancer. Co-author DOI 10.1200/op.22.00088↗
  23. Leveraging patient-reported outcomes (PROs) in patients with pancreatic cancer: The Pancreatic Cancer Action Network (PanCAN) online patient registry experienc… Co-author DOI 10.1002/cam4.4257↗
  24. Impact of PET/MRI in the Treatment of Pancreatic Adenocarcinoma: a Retrospective Cohort Study. Co-author DOI 10.1007/s11307-020-01569-7↗
  25. Conditional Survival in Resected Pancreatic Ductal Adenocarcinoma Patients Treated with Total Neoadjuvant Therapy. Co-author DOI 10.1007/s11605-020-04897-9↗
  26. Radiation therapy enhances immunotherapy response in microsatellite stable colorectal and pancreatic adenocarcinoma in a phase II trial. Co-author DOI 10.1038/s43018-021-00269-7↗
  27. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy. Co-author DOI 10.1093/jnci/djaa073↗
  28. Liver Metastasis-Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients: Data From a Multi-institu… Co-author DOI 10.1097/mpa.0000000000001822↗
  29. Refining the Molecular Framework for Pancreatic Cancer with Single-cell and Spatial Technologies. Co-author DOI 10.1158/1078-0432.ccr-20-4712↗
  30. Single-nucleus and spatial transcriptomics of archival pancreatic cancer reveals multi-compartment reprogramming after neoadjuvant treatment Co-author DOI 10.1101/2020.08.25.267336↗
  31. A Phase I Study of Dinaciclib in Combination With MK-2206 in Patients With Advanced Pancreatic Cancer. Co-author DOI 10.1111/cts.12802↗
  32. Phase Ib Study of Wnt Inhibitor Ipafricept with Gemcitabine and nab-paclitaxel in Patients with Previously Untreated Stage IV Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-0489↗
  33. A Phase Ib Study of Single-Agent Idelalisib Followed by Idelalisib in Combination with Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinom… Co-author DOI 10.1634/theoncologist.2020-0321↗
  34. The present and future of systemic and microenvironment-targeted therapy for pancreatic adenocarcinoma. Last author DOI 10.21037/apc-2020-pda-05↗
  35. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. Co-author DOI 10.3322/caac.21626↗
  36. Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical… Co-author DOI 10.1001/jamaoncol.2019.0892↗
  37. Results from a Phase IIb, Randomized, Multicenter Study of GVAX Pancreas and CRS-207 Compared with Chemotherapy in Adults with Previously Treated Metastatic Pa… Co-author DOI 10.1158/1078-0432.ccr-18-2992↗
  38. Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer. Co-author DOI 10.1007/s11523-016-0469-y↗
  39. MUC1 and HIF-1alpha Signaling Crosstalk Induces Anabolic Glucose Metabolism to Impart Gemcitabine Resistance to Pancreatic Cancer. Co-author DOI 10.1016/j.ccell.2017.06.004↗
  40. Patterns of Care for Locally Advanced Pancreatic Adenocarcinoma Using the National Cancer Database. Co-author DOI 10.1097/mpa.0000000000000876↗
  41. Pancreatic Adenocarcinoma, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. Co-author DOI 10.6004/jnccn.2017.0131↗
  42. A phase 1b study of erlotinib in combination with gemcitabine and nab-paclitaxel in patients with previously untreated advanced pancreatic cancer: an Academic … Co-author DOI 10.1007/s00280-016-2981-2↗
  43. Prognostic factors of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with meta… Co-author DOI 10.1634/theoncologist.2014-0394↗
  44. Pancreatic adenocarcinoma, version 2.2014: featured updates to the NCCN guidelines. Co-author DOI 10.6004/jnccn.2014.0106↗
  45. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with soli… Co-author DOI 10.1158/1078-0432.ccr-11-2813↗
  46. Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancer. Co-author DOI 10.1593/neo.111810↗
  47. Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10637-010-9413-7↗
  48. The many faces of wnt and pancreatic ductal adenocarcinoma oncogenesis. Co-author DOI 10.3390/cancers3033676↗

Trials 2

  1. FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer Principal investigator NCT05077800↗
  2. FOLFIRINOX + NIS793 in Pancreatic Cancer Principal investigator NCT05417386↗

Closest collaborators

The 25 strongest of 300 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jennifer Yon-Li Wo · 17 shared papers, 2019–2026 · strength 2.70
  2. Theodore Sunki Hong · 17 shared papers, 2019–2026 · strength 2.23
  3. David P. Ryan · 15 shared papers, 2019–2026 · strength 1.97
  4. David Tsai Ting · 12 shared papers, 2019–2026 · strength 1.62
  5. Motaz Qadan · 11 shared papers, 2019–2026 · strength 1.51
  6. Aparna R. Parikh · 11 shared papers, 2019–2026 · strength 1.51
  7. Lawrence Scott Blaszkowsky · 10 shared papers, 2019–2026 · strength 1.45
  8. Keith D. Lillemoe · 10 shared papers, 2019–2026 · strength 1.41
  9. Carlos Fernández-del Castillo · 9 shared papers, 2019–2026 · strength 1.38
  10. Priyadarshini Pathak · 5 shared papers, 2024–2026 · strength 1.29
  11. Cristina Rosa Ferrone · 10 shared papers, 2017–2024 · strength 1.09
  12. Hannah Johnson Roberts · 5 shared papers, 2024–2026 · strength 1.06
  13. William L. Hwang · 5 shared papers, 2020–2026 · strength 0.71
  14. Arnav Mehta · 5 shared papers, 2020–2026 · strength 0.63
  15. Brian Matthew Wolpin · 5 shared papers, 2014–2026 · strength 0.54
  16. Onofrio A. Catalano · 4 shared papers, 2021–2024 · strength 0.49
  17. Andrew Louis Warshaw · 4 shared papers, 2021–2023 · strength 0.47
  18. Thomas Adam Abrams · 3 shared papers, 2023–2026 · strength 0.47
  19. Matthew B.B. Yurgelun · 3 shared papers, 2023–2026 · strength 0.47
  20. James M. Cleary · 3 shared papers, 2023–2026 · strength 0.47
  21. Wells A. Messersmith · 6 shared papers, 2011–2025 · strength 0.47
  22. Carlos F. Fernandez-del Castillo · 4 shared papers, 2020–2023 · strength 0.46
  23. Giulio Belfiori · 2 shared papers, 2026 · strength 0.42
  24. Stefano Partelli · 2 shared papers, 2026 · strength 0.42
  25. Federico De Stefano · 2 shared papers, 2026 · strength 0.42

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.